Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CA2 | P00918 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157428 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL14084740 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL2807354 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL6050831 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL3558104 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL726729 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL3658220 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL2457046 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL6926105 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 | |
| SCHEMBL28927383 | 1.00 | MGLL (0.40) | MGLLCA1CA2ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713017-A1 | CHIMERIC MOLECULE | UCL Business Ltd (GB) | 2026-03-25 | — | — | EP | claimed |
| US-12496564-B2 | Dehydrogenation reaction apparatus and system including the same | HYUNDAI MOTOR COMPANY (KR) | 2025-12-16 | — | — | US | claimed |
| US-12466812-B2 | Pyridinyltriazine derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, ameliorating, or treating cancer comprising same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-11-11 | — | — | US | claimed |
| US-12391706-B2 | Multi-target tyrosine kinase inhibitor | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2025-08-19 | — | — | US | claimed |
| US-20250206980-A1 | POLYUREA COPOLYMER COATING COMPOSITIONS AND METHODS | INNOVATIVE SURFACE TECH INC (US) | 2025-06-26 | — | — | US | claimed |
| EP-3870285-B1 | SYNTHESIS OF ESUBERAPROST PRODRUGS | UNITED THERAPEUTICS CORP (US) | 2025-06-18 | — | — | EP | claimed |
| CN-119039492-B | Styrene macroporous strong base anion resin and preparation method thereof | 安徽一帆新材料科技有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-119875044-A | Preparation method and application of super-alkali-resistant bipiperidinium cross-linked anion exchange membrane | 宿迁时代储能科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119823027-A | Piperidinyl piperidine modified beta-carboline open ring compound, and preparation method and application thereof | 南通大学 | 2025-04-15 | — | — | CN | claimed |
| US-12269963-B2 | Polyurea copolymer coating compositions and methods | INNOVATIVE SURFACE TECHNOLOGIES, INC. (US) | 2025-04-08 | — | — | US | claimed |
| EP-0729468-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0729468-A4 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1996-07-12 | — | — | EP | claimed |
| EP-0535250-B1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO (JP) | 1996-06-19 | — | — | EP | claimed |
| EP-0699665-A1 | Imidazoline derivatives, their preparation and their use as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | claimed |
| EP-0699674-A1 | 1-Aryl-2-acetylamidopentanone derivatives for use as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | claimed |
| EP-0686629-A2 | Cyclohexyl tachykinine receptor antagonists | ELI LILLY AND COMPANY (US) | 1995-12-13 | — | — | EP | claimed |
| WO-1995014017-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1995-05-26 | — | — | WO | claimed |
| US-5344845-A | Methyl 4(4-acetoxy-3-methoxycinnamanide and salts as an immunosuppressive drug for allergic reactions | TSUMURA & CO. (JP) | 1994-09-06 | — | — | US | claimed |
| EP-0535250-A1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO. (JP) | 1993-04-07 | — | — | EP | claimed |
| EP-0029592-A1 | A coating composition based on acrylic polymer blends, articles coated therewith, and process for preparing said coated articles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-06-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391706-B2 | Multi-target tyrosine kinase inhibitor | LCK, ABL1, DSTYK | MGLL 3318/4885CA1 3745/4885CA2 2518/4885 |
| US-12466812-B2 | Pyridinyltriazine derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, ameliorating, or treating cancer comprising same | FGFR3, FGFR1, FGFR4 | MGLL 4628/4885CA1 2655/4885CA2 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.